More than 200 researchers braved dizzying altitude, howling coyotes, and a fairly brooding mood in light of elusive trial success, to exchange the latest on Alzheimer's and Parkinson’s diseases in joint symposia held March 2-7 in Keystone, Colorado. Between plenary and parallel talks, bustling poster sessions, and the odd foray to the slopes, scientists discussed trial design, genetics, pathology, biomarkers, and cell and protein biology.
Combination therapies may work where single drugs fall short, but testing them in AD may prove challenging.
A Keystone symposium underscores the role of lysosomal dysfunction and vesicle trafficking in neurodegenerative disease.
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
Keystone presenters pulled out new tools to make connections between genetics and disease.